• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Belantamab mafodotin extends PFS among patients with advanced multiple myeloma

by | Nov 28, 2023 | Uncategorized

Belantamab mafodotin improved PFS — when combined with bortezomib and dexamethasone — as second-line treatment among patients with relapsed or refractory multiple myeloma, according to topline data from the agent’s manufacturer.Belantamab mafodotin (Blenrep, GSK) is...

Survival May Not Differ by Race in Multiple Myeloma Treated With Abecma

by | Nov 6, 2023 | Uncategorized

Source: CureToday articles Researchers have found that, among patients with relapsed/refractory multiple myeloma who received treatment with the CAR-T cell therapy Abecma, race and ethnicity played roles in safety and response but not survival. Read...

CAR-T outcomes for multiple myeloma similar regardless of race, ethnicity

by | Oct 30, 2023 | Uncategorized

Black, Hispanic and white individuals treated with idecabtagene vicleucel for relapsed or refractory multiple myeloma experienced similar PFS and OS, according to study results published in Blood Advances.The findings should be confirmed in larger samples of diverse...

My Journey Through Multiple Myeloma: A Rebirth

by | Oct 25, 2023 | Uncategorized

Source: CureToday articles Braving the storm that is cancer. Read More

To Improve Multiple Myeloma Survival, Diabetes Management Cannot Be Ignored

by | Oct 17, 2023 | Uncategorized

Source: CureToday articles Patients with cancer and diabetes need to carefully co-manage both diseases, as one expert tells CURE. Read More

New Trial Doses STAR-LLD in Patients With Multiple Myeloma

by | Oct 14, 2023 | Uncategorized

Source: CureToday articles A new phase 1 trial is testing their first patients with STAR-LLD in the treatment of patients with multiple myeloma. Read More
« Older Entries
Next Entries »

Recent Content

  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
  • Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
  • Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
  • A Year of Resilience: Looking Back After a Myeloma Diagnosis
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT